KR900001364A - 정맥주사용 약학적 조성물 및 이를 제조하는 방법 - Google Patents

정맥주사용 약학적 조성물 및 이를 제조하는 방법 Download PDF

Info

Publication number
KR900001364A
KR900001364A KR1019890010365A KR890010365A KR900001364A KR 900001364 A KR900001364 A KR 900001364A KR 1019890010365 A KR1019890010365 A KR 1019890010365A KR 890010365 A KR890010365 A KR 890010365A KR 900001364 A KR900001364 A KR 900001364A
Authority
KR
South Korea
Prior art keywords
polyethylene glycol
group
cyclosporin
member selected
component
Prior art date
Application number
KR1019890010365A
Other languages
English (en)
Other versions
KR0137674B1 (ko
Inventor
오르반 에르노
바로흐 티보르
이라 라조스
앰부르스 기보르
제켈 니이 보카니 안토니아
엘크 산도르
토모리 니이 조스즈트 에바
실크로시 라조스
토드 사루리 에바
모라브크시크 임레
엘케스 이스트반
Original Assignee
이스트반 크세르누스, 죠즈세프 엠티
비오갈 기요기스제트기야르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이스트반 크세르누스, 죠즈세프 엠티, 비오갈 기요기스제트기야르 filed Critical 이스트반 크세르누스, 죠즈세프 엠티
Publication of KR900001364A publication Critical patent/KR900001364A/ko
Application granted granted Critical
Publication of KR0137674B1 publication Critical patent/KR0137674B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

정맥주사용 약학적 조성물 및 이를 제조하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 및 제 2도 제 3도는 본 발명의 조성물 및 대조조성물의 수축기 및 이완기 혈압에 대한 효과를 나타낸 그라프이다.

Claims (14)

  1. a) 1종 이상의 사이클로스포린류 1중량부, b) 포화 하이드록실화 지방산과 폴리에틸렌글리콜과의 모노에스테르 또는 이들 모노에스테르류의 혼합물 8-13중량부, 및 정맥투여가 가능한 1가 또는 다가 알콜류 1종 이상 4-10중량부를 함유하는 활성성분으로 사이클로스포린류를 함유하는 정맥주사용 약학적 조성물.
  2. 제 1항에서, 사이클로스포린으로서 사이클로스포린 A, 사이클로스포린 C 및 사이클로스포린 G로 이루어진 그룹으로부터 선택된 1종 이상을 함유하는 조성물.
  3. 제 1항에서, C10-C22포화 하이드록실화 지방산과 분자량 600-1300의 폴리에틸렌글리콜(PEG)과의 모노에스테르류로 이루어진 그룹에서 선택된 1종 이상을 함유하는 조성물
  4. 제 1항에서, C14-C22포화 하이드록실화 지방산과 분자량 750-1100의 폴리에틸렌글리콜(PEG)과의 모노에스테르류로 이루어진 그룹으로부터 선택된 1종 이상을 성분 b)를 함유하는 조성물
  5. 제 1항에서 폴리에틸렌글리콜-9-하이드록시미리스테이트, 폴리에틸렌글리콜-9-하이드록시팔미테이트 또는 폴리에틸렌글리콜-12-하이드록시스테아레이트로 이루어진 그룹중에서 선택된 1종 이상을 성분 b)로 함유하는 조성물.
  6. 제 1항에서, 폴리에틸렌글리콜-660-12-하이드록시스테아레이트를 성분 b)로 함유하는 조성물.
  7. 제 1항에서, 에틸알콜, 프로필렌글리콜, 글리세린 및/또는 폴리에틸글리콜로 이루어진 그룹에서 선택된 1종 이상을 성분 c)로 함유하는 조성물.
  8. a) 1종 이상의 사이클로스포린 1중량부, b) 포화 하이드록실화 지방산과 폴리에틸렌글리콜의 모노에스테르류 또는 이들 모노에스테르류의 혼합물 8-13중량부, c) 정맥투여가 가능한 1가-또는 다가알콜류 4-10중량부를 혼합하여 활성성분으로 사이클로스포린류를 함유하는 약학적 조성물을 제조하는 방법.
  9. 제 8항에서, 사이클로스포린으로 사이클로스포린 A, 사이클로스포린 C 및 사이클로스포린 G로 이루어진 그룹에서 선택된 1종 이상을 함유하는 방법.
  10. 제 8항에서, C10-C22포화 하이드록실화 지방산과 분자량 600-1300의 폴리에틸렌글리콜(PEG) 모노에스테르류로 이루어진 그룹에서 선택된 1종 이상을 함유하는 조성물
  11. 제 8항에서, C14-C22포화 하이드록실화 지방산과 분자량 750-1100의 폴리에틸렌글리콜(PEG)의 모노에스테르류로 이루어진 그룹에서 선택된 1종 이상을 성분 b)로서 사용하는 방법.
  12. 제8항에서, 폴리에틸렌글리콜-9-하이드록시미리스테이트, 폴리에틸렌글리콜-9-하이드록시팔미테이트 또는 폴리에틸렌글리콜-12-하이드록시스테아레이트로 이루어진 그룹에서 선택된 1종 이상을 성분 b)로 사용하는 방법.
  13. 제 8항에서, 폴리에틸렌글리콜-600-12-하이드록시스테아레이트를 성분 b)로서 사용하는 방법.
  14. 에틸알콜, 프로필알콜, 글리세린 및/또는 폴리에틸렌글리콜로 이루어진 그룹에서 선택된 1종 이상을 성분 c)로 사용하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890010365A 1988-07-21 1989-07-21 정맥주사용 약학적 조성물 및 이를 제조하는 방법 KR0137674B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU2251-3796 1988-07-21
HU883796A HU201567B (en) 1988-07-21 1988-07-21 Process for production of intravenous medical compositions containing cyclosphorin

Publications (2)

Publication Number Publication Date
KR900001364A true KR900001364A (ko) 1990-02-27
KR0137674B1 KR0137674B1 (ko) 1998-05-15

Family

ID=10965544

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890010365A KR0137674B1 (ko) 1988-07-21 1989-07-21 정맥주사용 약학적 조성물 및 이를 제조하는 방법

Country Status (26)

Country Link
US (1) US5047396A (ko)
JP (1) JPH07116051B2 (ko)
KR (1) KR0137674B1 (ko)
AR (1) AR243382A1 (ko)
AT (1) AT402258B (ko)
AU (1) AU614862B2 (ko)
BE (1) BE1004323A4 (ko)
CA (1) CA1332712C (ko)
CH (1) CH679120A5 (ko)
DD (1) DD283934A5 (ko)
DE (1) DE3924207A1 (ko)
DK (1) DK175540B1 (ko)
FI (1) FI92556C (ko)
FR (1) FR2635265B1 (ko)
GB (1) GB2221157B (ko)
GR (1) GR1002184B (ko)
HU (1) HU201567B (ko)
IL (1) IL91069A (ko)
IT (1) IT1231434B (ko)
LU (1) LU87560A1 (ko)
NL (1) NL194578C (ko)
NO (1) NO175287C (ko)
NZ (1) NZ230036A (ko)
PT (1) PT91246B (ko)
SE (1) SE509174C2 (ko)
ZA (1) ZA895588B (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
DK0642332T3 (da) * 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
PT589843E (pt) 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
DE4412201A1 (de) * 1993-04-20 1994-11-10 Rentschler Arzneimittel Neue pharmazeutische Zubereitungen zur oralen Verabreichung enthaltend Cyclosporin
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
AU715165B2 (en) 1994-11-03 2000-01-20 Novartis Ag Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
JP3009742B2 (ja) * 1995-08-25 2000-02-14 サングスタット メディカル コーポレイション 経口用シクロスポリン製剤
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US20050053594A1 (en) * 1995-11-16 2005-03-10 Dario Alessi RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK
DE19549852B4 (de) * 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
CN1679917A (zh) 1997-01-30 2005-10-12 诺瓦提斯公司 包含环孢菌素a的无油药物组合物
KR100966245B1 (ko) * 1997-03-12 2010-06-28 아보트 러보러터리즈 사이클로스포린 투여용 친수성 2원 시스템
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
AT408186B (de) * 1998-12-15 2001-09-25 Sanochemia Pharmazeutika Ag Wässerige zubereitung von beta-carotin
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
FR2826517B1 (fr) * 2001-06-20 2004-03-12 Somfy Dispositif d'alimentation pour store motorise ou similaire
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
JP4815418B2 (ja) * 2007-10-19 2011-11-16 カヤバ工業株式会社 空圧緩衝器
JP6002385B2 (ja) 2008-09-12 2016-10-05 クリティカル ファーマシューティカルズ リミテッドＣｒｉｔｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 医薬組成物、医薬組成物における吸収促進剤の使用方法、及び医薬組成物の製造方法
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
SI2683406T1 (sl) 2011-03-11 2019-10-30 Beth Israel Deconess Medical Center Inc Protitelesa ANTI-CD40 in njihova uporaba
MX2018002708A (es) 2015-09-04 2018-08-01 Primatope Therapeutics Inc Anticuerpos anti-cd40 humanizados y usos de los mismos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3658M (fr) * 1964-02-18 1965-11-02 Michel Marie Andre Guerbet Composition huileuse pour l'injection intravasculaire.
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH641356A5 (en) * 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
AU534955B2 (en) * 1980-01-23 1984-02-23 Sandoz Ag Cyclosporin a to treat lymphoproliferative disorders
DE3339235A1 (de) * 1983-10-28 1985-05-09 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von polyurethanen
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
AU611961B2 (en) * 1987-10-02 1991-06-27 Vsesojuzny Kardiologichesky Nauchny Tsentr Akademii Meditsinskikh Nauk Sssr Pharmaceutical preparation for curing multiple sclerosis and lateral amyotrophic sclerosis
GB8729153D0 (en) * 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
US4943560A (en) * 1988-04-06 1990-07-24 Regents Of The University Of Minnesota Solvent system for chronic vascular infusion of hydrophobic drugs
DE3832362A1 (de) * 1988-09-23 1990-03-29 Sandoz Ag Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
US5047396A (en) 1991-09-10
IT1231434B (it) 1991-12-04
AU614862B2 (en) 1991-09-12
IL91069A (en) 1993-07-08
FI893520A (fi) 1990-01-22
JPH07116051B2 (ja) 1995-12-13
DE3924207A1 (de) 1990-01-25
DK175540B1 (da) 2004-11-29
NL194578B (nl) 2002-04-02
FR2635265A1 (fr) 1990-02-16
JPH03115227A (ja) 1991-05-16
ZA895588B (en) 1990-07-25
NO175287B (no) 1994-06-20
SE8902588D0 (sv) 1989-07-21
NO892995D0 (no) 1989-07-21
GB8916679D0 (en) 1989-09-06
FI92556B (fi) 1994-08-31
CA1332712C (en) 1994-10-25
NO892995L (no) 1990-01-22
LU87560A1 (fr) 1991-02-18
DD283934A5 (de) 1990-10-31
GB2221157A (en) 1990-01-31
GB2221157B (en) 1991-12-18
KR0137674B1 (ko) 1998-05-15
AT402258B (de) 1997-03-25
AR243382A1 (es) 1993-08-31
HUT50851A (en) 1990-03-28
PT91246A (pt) 1990-02-08
CH679120A5 (ko) 1991-12-31
FR2635265B1 (fr) 1995-03-17
ATA176789A (de) 1996-08-15
PT91246B (pt) 1995-05-04
DE3924207C2 (ko) 1992-07-09
IT8921259A0 (it) 1989-07-21
NO175287C (no) 1994-09-28
SE8902588L (sv) 1990-01-22
DK362189A (da) 1990-01-22
FI92556C (fi) 1994-12-12
NL8901902A (nl) 1990-02-16
GR1002184B (en) 1996-03-12
BE1004323A4 (fr) 1992-11-03
NZ230036A (en) 1991-02-26
FI893520A0 (fi) 1989-07-21
NL194578C (nl) 2002-08-05
AU3884589A (en) 1990-02-01
DK362189D0 (da) 1989-07-21
SE509174C2 (sv) 1998-12-14
GR890100467A (el) 1990-06-27
HU201567B (en) 1990-11-28

Similar Documents

Publication Publication Date Title
KR900001364A (ko) 정맥주사용 약학적 조성물 및 이를 제조하는 방법
JP6386609B2 (ja) エキノキャンディン系化合物のための投与レジメン
KR100587551B1 (ko) 오메가-3 지방산 오일을 함유하는 약학 조성물
EE03425B1 (et) Lihtsa koostise ja kõrge biosaadavusega tsüklosporiini preparaadid suu kaudu manustamiseks ja nende valmistamismeetod
AP2000001943A0 (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
CO4930289A1 (es) Composiciones galenicas, en donde el ingrediente activo es un agente activo dificilmente soluble
KR900004348A (ko) 시클로스포린을 함유하는 약학 조성물
EP1658858A3 (en) Use of botulinum toxin for the treatment of unstable bladder
KR960016903A (ko) 경구용 제약 제조물
DE69403057D1 (de) Zusammensetzung, die bei peroraler verabreichung eine mikroemulsion bildet
KR970064620A (ko) 사이클로스포린-함유 외용약제 조성물
KR950002747A (ko) 사이클로스포린 연질캅셀제 조성물
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
DE60132103T2 (de) Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
EP2181706A3 (en) Florfenicol esters for treating bacterial infections
MXPA05001352A (es) Formulacion farmaceutica que comprende ciclosporina, ester de glicol de propileno y agente tensoactivo no ionico.
JP3862273B2 (ja) 経口投与用シクロスポリン含有新規製剤
KR970706803A (ko) 경구용 시클로스포린 제형(oral cyclosporin formulations)
KR950007857A (ko) 경구투여용 라파마이신 제제
KR900700448A (ko) 불포화 측쇄를 갖는 1α-히드로시비타민 D동족체
ZA200104828B (en) Cyclosporin solution.
JP2006062968A (ja) むくみ改善剤
JPS5679626A (en) Semi-solid medicine
KR970032876A (ko) 간장질환 치료용 의약 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100204

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee